849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Meritup Breast Cancer	Chung Shan Medical University	P2	CC (47)
mhb036c for Breast Cancer	Minghui Pharmaceutical (Hangzhou) Ltd	P2	CC (47)
mhb039a for Breast Cancer	Minghui Pharmaceutical (Hangzhou) Ltd	P2	CC (47)
Omega-N-Methylarginine Breast Cancer	The Methodist Hospital Research Institute	P2	CC (47)
Samfenet Breast Cancer	Seoul National University Hospital	P2	CC (47)
shr2554 Breast Cancer	Henan Cancer Hospital	P2	CC (47)
Shr-A1921 Breast Cancer	Fudan University	P2	CC (47)
Shr-A2102 Breast Cancer	Fudan University	P2	CC (47)
sys6023 Breast Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P2	CC (47)
Tiragolumab Breast Cancer	The Netherlands Cancer Institute	P2	CC (47)
Trastuzumab Deruxtecan For Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CC (47)
Trastuzumab Imbotolimod Breast Cancer	Bolt Biotherapeutics, Inc.	P2	CC (47)
Trastuzumab Rezetecan Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CC (47)
bb-1701 Breast Cancer	Eisai Inc.	P2	CC (46)
Byon5667 Breast Cancer	Byondis B.V.	P1/2	CC (46)
Cypep-1 Breast Cancer	Cytovation AS	P1/2	CC (46)
Hetrombopag Breast Cancer	Fudan University	P2	CC (46)
Itraconazole Breast Cancer	Shandong Suncadia Medicine Co., Ltd.	P1	CC (46)
Kenacort Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Lisinopril Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P2	CC (46)
Methadon Breast Cancer	University of Utah	P3	CC (46)
Methylene Blue Breast Cancer	BTG International Inc.	P2	CC (46)
Oleogel-S10 Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Pantoprazole Breast Cancer	Cairo University	P2	CC (46)
Replens Breast Cancer	Alta Bates Summit Medical Center	P2	CC (46)
rp12146 Breast Cancer	Rhizen Pharmaceuticals SA	P1	CC (46)
Silymarin Breast Cancer	Tanta University	P2/3	CC (46)
wh002 Breast Cancer	Beijing Wehand-Bio Pharmaceutical Co., Ltd	P2	CC (46)
Zotatifin Breast Cancer	Jennifer Lee Caswell-Jin	P2	CC (46)
Amcenestrant Breast Cancer	Sanofi	P3	CC (45)
Avelumab Breast Cancer	The Christie NHS Foundation Trust	P2	CC (45)
Balstilimab Breast Cancer	Yuan Yuan	P1/2	CC (45)
Cea Car-T Cells Breast Cancer	Chongqing Precision Biotech Co., Ltd	P1/2	CC (45)
Cea-Targeted Car-T Breast Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1/2	CC (45)
hs-10352 Breast Cancer	Henan Cancer Hospital	P1/2	CC (45)
Interferon Alpha-2 Breast Cancer	Roswell Park Cancer Institute	P1/2	CC (45)
Ivermectin Breast Cancer	Yuan Yuan	P1/2	CC (45)
Naxitamab Breast Cancer	Margaret Gatti-Mays	P1/2	CC (45)
Tivozanib Breast Cancer	University of Florida	P1/2	CC (45)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells Breast Cancer	Margaret Gatti-Mays	P1/2	CC (45)
18F-ASIS Breast Cancer	Var2 Pharmaceuticals	P1	CC (44)
ab-201 Breast Cancer	GC Cell Corporation	P1/2	CC (44)
Cdx 1140 Breast Cancer	University of Southern California	P1	CC (44)
Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Breast Cancer	M.D. Anderson Cancer Center	P2	CC (44)
68GaNOTA-Anti-HER2 VHH1 Breast Cancer	Centre Henri Becquerel	P2	CC (43)
[99mTc]Tc-HYNIC-FAPI Breast Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P1	CC (43)
Abbv-461 Breast Cancer	Calibr, a division of Scripps Research	P1	CC (43)
Adebrelimab Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CC (43)
Aguix Breast Cancer	Brigham and Women's Hospital	P2	CC (43)
and019 po qd Breast Cancer	Kind Pharmaceuticals LLC	P1	CC (43)

Showing 401 to 450 of 849 assets

PreviousPage 9 of 17Next